Probiotics combined with rifaximin influence the neurometabolic changes in a rat model of type C HE.
Details
Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY 4.0
UNIL restricted access
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_CB549E4C49B7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Probiotics combined with rifaximin influence the neurometabolic changes in a rat model of type C HE.
Journal
Scientific reports
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Publication state
Published
Issued date
09/09/2021
Peer-reviewed
Oui
Volume
11
Number
1
Pages
17988
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Publication Status: epublish
Abstract
Type C hepatic encephalopathy (HE) is a neuropsychiatric disease caused by chronic liver disease. Management of type C HE remains an important challenge because treatment options are limited. Both the antibiotic rifaximin and probiotics have been reported to reduce the symptoms of HE, but longitudinal studies assessing their effects on brain metabolism are lacking and the molecular mechanisms underpinning their effects are not fully understood. Therefore, we evaluated in detail the effects of these different treatments on the neurometabolic changes associated with type C HE using a multimodal approach including ultra-high field in vivo <sup>1</sup> H MRS. We analyzed longitudinally the effect of rifaximin alone or in combination with the probiotic Vivomixx on the brain metabolic profile in the hippocampus and cerebellum of bile duct ligated (BDL) rats, an established model of type C HE. Overall, while rifaximin alone appeared to induce no significant effect on the neurometabolic profile of BDL rats, its association with the probiotic resulted in more attenuated neurometabolic alterations in BDL rats followed longitudinally (i.e. a smaller increase in Gln and milder decrease in Glu and Cr levels). Given that both rifaximin and some probiotics are used in the treatment of HE, the implications of these findings may be clinically relevant.
Keywords
Animals, Anti-Bacterial Agents/therapeutic use, Bilirubin/blood, Cerebellum/metabolism, Disease Models, Animal, Hepatic Encephalopathy/blood, Hepatic Encephalopathy/diet therapy, Hepatic Encephalopathy/drug therapy, Hippocampus/metabolism, Longitudinal Studies, Male, Metabolome/drug effects, Probiotics/therapeutic use, Proton Magnetic Resonance Spectroscopy/methods, Rats, Rats, Wistar, Rifaximin/therapeutic use, Signal Transduction/drug effects, Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
21/09/2021 13:57
Last modification date
20/07/2022 6:39